Biomarker Research · 2024 · 72 citations · 99 references
Life SciencesImmunologyOncologyCancer ImmunologyDrug DeliveryImmunotherapyCancer ImmunotherapyCancer NanomedicineDrug EncapsulationNanocarriers For TherapeuticsNanomedicineNanoparticle DesignCancer Immunotherapy NanoparticlesInnate Antitumor ImmunityInnate Immune EffectorsMultifunctional NanoplatformsNanoparticle-based ImmunotherapyPro-inflammatory ChemokinesTumor PenetrationTumor Vasculature Normalization
The cGAS-STING signaling pathway has emerged as a critical mediator of innate immune responses, playing a crucial role in improving antitumor immunity through immune effector responses. Targeting the cGAS-STING pathway holds promise for overcoming immunosuppressive tumor microenvironments (TME) and promoting effective tumor elimination. However, systemic administration of current STING agonists faces challenges related to low bioavailability and potential adverse effects, thus limiting their clinical applicability. Recently, nanotechnology-based strategies have been developed to modulate TMEs for robust immunotherapeutic responses. The encapsulation and delivery of STING agonists within nanoparticles (STING-NPs) present an attractive avenue for antitumor immunotherapy. This review explores a range of nanoparticles designed to encapsulate STING agonists, highlighting their benefits, including favorable biocompatibility, improved tumor penetration, and efficient intracellular delivery of STING agonists. The review also summarizes the immunomodulatory impacts of STING-NPs on the TME, including enhanced secretion of pro-inflammatory cytokines and chemokines, dendritic cell activation, cytotoxic T cell priming, macrophage re-education, and vasculature normalization. Furthermore, the review offers insights into co-delivered nanoplatforms involving STING agonists alongside antitumor agents such as chemotherapeutic compounds, immune checkpoint inhibitors, antigen peptides, and other immune adjuvants. These platforms demonstrate remarkable versatility in inducing immunogenic responses within the TME, ultimately amplifying the potential for antitumor immunotherapy.
99
Liposome: classification, preparation, and applications
Abolfazl Akbarzadeh, Rogaie Rezaei-Sadabady, Soodabeh Davaran et al. · Nanoscale Research Letters · 2013 · 3.5K citations · Full text
Structural basis of STING binding with and phosphorylation by TBK1
Conggang Zhang, Guijun Shang, Xiang Gui et al. · Nature · 2019 · 1.1K citations
A STING-activating nanovaccine for cancer immunotherapy
Min Luo, Hua Wang, Zhaohui Wang et al. · Nature Nanotechnology · 2017 · 889 citations
Life Sciences, Immunology, Oncology +14
Design of amidobenzimidazole STING receptor agonists with systemic activity
Joshi M. Ramanjulu, G. Scott Pesiridis, Jingsong Yang et al. · Nature · 2018 · 865 citations